Publications and Presentations
ASPIRE-FTD: A Phase 1/2 Clinical Trial to Evaluate AVB-101 in FTD with GRN Mutations: Study Update
Date: Sep 19, 2024
Conference / Journal: ISFTD 2024
Author(s): Jane Chan
ASPIRE-FTD: A Phase 1/2 Clinical Trial to Evaluate AVB-101 in FTD with GRN mutations (FTD-GRN)
Date: Sep 19, 2024
Conference / Journal: ISFTD 2024
Author(s): Jane Chan
Pre-Clinical Development of AVB-101, an AAV Gene Therapy Treatment for Frontotemporal Dementia with Progranulin Mutations
Date: Jul 28, 2024
Conference / Journal: AAIC 2024
Author(s): Youn Bok Lee PhD
vMiX™, an Innovative AAV-Based RNA Interference Platform: First Applications to Treat ALS
Date: May 10, 2024
Conference / Journal: ASGCT 2024
Author(s): Romain Joubert PhD
vMiX™: Towards a “Plug-and-Play” Platform for Gene Silencing Therapy in Neurodegenerative Diseases
Date: May 10, 2024
Conference / Journal: ASGCT 2024
Author(s): Catia Andreassi PhD
AVB-101 Six-month Preclinical Safety and Biodistribution Data Following Intrathalamic Delivery to Cynomolgus Monkeys Demonstrates Good Tolerability and Widespread Progranulin Expression in Brain Tissues
Date: Oct 25, 2023
Conference / Journal: ESGCT 2023
Author(s): Carlos J Miranda PhD
Intrathalamic Delivery of AVB-101 Rescues Pathology in Progranulin Deficient Mice and Achieves Widespread Cortical Expression in Two Large Animal Models
Date: Nov 4, 2022
Conference / Journal: ISFTD 2022
Author(s): Prof Chris Shaw
Intrathalamic Delivery of AVB-101 Rescues Pathology in Grn Null Mice and Achieves Widespread Cortical Expression in a Large Animal Model
Date: Oct 13, 2022
Conference / Journal: ESGCT 2022
Author(s): Youn Bok Lee, PhD